AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04056000 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-carbohdyrate breakfast
Description: Ingestion of a high-carbohydrate breakfast 60 minutes before exercise
Study NCT04056000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 60-minutes of steady state exercise
Description: See intervention name
Study NCT01021488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg/d for 14days
Description: Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
Study NCT01021488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin only
Description: enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
Study NCT03084068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human dehydrated umbilical cord allograft
Description: human dehydrated umbilical cord allograft
Study NCT03084068 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Open rotator cuff surgery with standard suture repair
Study NCT03905356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Certified exercise oncology specialists will personalize, prescribe, and guide ET, including twice weekly resistance training and walking, performed at home, with supervision in the Exercise Medicine Unit. The cancer exercise physiologist will teach participants proper warm ups, use of equipment, exercise form, modes of activity, intensity of exercise, flexibility exercises, and cool down. In addition, patients will be instructed to exercise on their own, at home, according to the instructions from the cancer exercise specialist.
Study NCT02035397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Study NCT02035397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum Toxin Type A
Study NCT02035397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Study NCT03406000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE (U300)
Description: Pharmaceutical form: Solution for Injection~Route of administration: Subcutaneous injection
Study NCT00297778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Dopamine agonist
Study NCT00297778 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00591604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D, 50,000IU,once weekly for 8 weeks, then every other week for 4 weeks
Study NCT04612478 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-Directed Exercise Program
Description: The full SDEP program, which will be developed by physical therapists, orthopaedic trauma surgeons, and investigators with experience in health behavior change, will be designed to maximize adherence/compliance with the program
Study NCT04612478 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinic-Based Physical
Description: Patients will be referred to PT by the orthopaedic surgeon for enrollment into a clinic-based PT program per usual referral patterns at the surgeon's center. Patients will receive services based on their health care benefits defined by his or her insurance plan.
Study NCT02539238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Longitudinal practice and real-time feedback
Description: Brief CPR practice distributed during working hours with real-time feedback
Study NCT02539238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Longitudinal practice and real-time feedback
Description: Brief CPR practice distributed during working hours with real-time feedback
Study NCT02044614 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Adjuvant Peritoneal Dialysis in the context of ongoing Hemodialysis
Study NCT03719378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre Operative Oral Fluids
Description: Patients will be self hydrating prior to their total knee replacement.
Study NCT02679547 — intervention group
Intervention type: OTHER
Intervention: Breastfeeding
Description: All of the participants and patients will have a questionnaire about their breastfeeding
Study NCT04112641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Daily oral ingestion of 1 g/day NIAGEN in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
Study NCT04112641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Daily oral ingestion of placebo in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
Study NCT03144778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT03144778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT02157129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipoAerosol© inhalation
Description: LipoAerosol© inhalation, 5x/d for 30min
Study NCT04240860 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platlet rich plasma
Description: Drug: PRP PRP subendometrial infusion~Device: ovum oickup needle PRP subendometrial infusion by hysteroscopic guided ovum pickup needle day 9 of the cycle
Study NCT04240860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial scratch
Description: Three Snip Hysteroscopic Endometrial Scratching in luteal phase of preceeding cycle
Study NCT01625208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined nerve block
Description: Combined supraclavicular brachial plexus block plus ulnar or median nerve block (depending on the location of surgery)
Study NCT01625208 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular block
Description: Standard supraclavicular brachial plexus block
Study NCT03515629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2810/ipi
Description: REGN2810 plus ipilimumab
Study NCT03515629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2810/chemo/ipi
Description: REGN2810 plus chemotherapy plus Ipilimumab
Study NCT03515629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Reference drug administered IV infusion
Study NCT03161626 — intervention group
Intervention type: DRUG
Intervention: Coagadex
Description: Plasma-driven blood coagulation factor X concentration
Study NCT01433744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Patients included in the test group were submitted to a non-surgical periodontal treatment protocol, which consisted of oral hygiene orientation and motivation followed by mechanical plaque control involving scaling and root planning using Gracey curets (Hu-Friedy Manufacturing, Chicago, IL, USA) and ultrasonic instrumentation (Cavitron Ultrasonics, Long Island City, NY, USA), under local anesthesia (Mepivacaine 2% with epinephrine 1:100000). The treatment was performed in one or two sessions depending on the extension of the patient's periodontal condition. Patients that presented teeth unreasonable to treat due to advanced periodontitis, or any other condition were extracted under local anesthesia.
Study NCT04205149 — intervention group
Intervention type: OTHER
Intervention: ERAS post-operative pathway
Description: ERAS Pathway
Study NCT04217005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensory Feedback
Description: Subjects will receive a sensory feedback provided by electrical stimulation
Study NCT04615156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-2-fluoro-2-deoxy-D-glucose
Description: Administration of 18F-2-fluoro-2-deoxy-D-glucose for the purposes of diagnosis.
Study NCT02629549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTL38
Description: Infusion of OTL38 prior to surgery
Study NCT02359890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERMOCOOL® SMARTTOUCH® (RF ablation treatment)
Description: Radiofrequency Ablation Treatment
Study NCT04127409 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Chicken-meat
Study NCT04127409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Chicken-meat
Study NCT04127409 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Eggs
Study NCT04127409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Eggs
Study NCT04127409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omega-3-PUFA Enriched Chicken-meat
Study NCT04127409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omega-3PUFA Enriched Eggs
Study NCT04645095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.
Study NCT04645095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hot pack
Description: All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.
Study NCT03849781 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeoBeat with a visible display
Description: NeoBeat (Laerdal Medical) is a CE approved novel heart rate meter, able to detect heart rate in newborns within seconds of birth. The NeoBeat uses ECG dry-electrodes in a snug-fit abdomen-shaped buckle for rapid application around the newborn's abdomen or thorax. It allows healthcare providers to reliably assess heart rate of the newborn immediately after birth and continuously during resuscitation.
Study NCT01066052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-hGH
Description: Subcutaneous administration.
Study NCT02235233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Technetium Tc 99M Mebrofenin
Description: Each subject will be injected with \~2.5 mCi of Technetium Tc 99M Mebrofenin
Study NCT02235233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Tc 99M Mebrofenin
Description: Each subject will be injected with \~2.5 mCi of Technetium Tc 99M Mebrofenin
Study NCT03841383 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echo stress dipyridamole
Description: Echo stress dipyridamole
Study NCT01323881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation
Description: Intermittent theta burst stimulation with 1200 pulses or sham stimulation over the ipsilesional M1 hand region for 10 daily sessions in 2 weeks.
Study NCT03197402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine-enriched protein gel delivery system
Description: Leucine enriched
Study NCT03197402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk protein gel delivery system
Description: Non-leucine enriched
Study NCT00977002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Pressure Noninvasive ventilation
Description: Patients randomized to this group are submitted to positive pressure noninvasive ventilation for 12 hours or more. Children younger than one year use nasal prong and older than one year use nasal or facial mask. A blood gas is collected in the moment of intubation and one hour after.
Study NCT00977002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhalatory O2
Description: Patients randomized to this group are submitted to inhalatory O2 using mask or nasal catheter. A blood gas is collected in the moment of intubation and one hour after.
Study NCT00619385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: Proellex 25 mg capsules 100 mg, 150 mg or 200mg daily for 7 days
Study NCT02512913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted/enhanced MAPS
Description: The plan is for recruitment at the first prenatal care visit followed by a proposed eight-session phone counseling sequence for the women, consistent with the session frequency in the original MAPS intervention: 1st call at 14 weeks gestation (75% of Romanian women begin prenatal care in 1st trimester), three monthly calls through the 2nd trimester (18-22-26 weeks gestation), a 5th and 6th calls in the 3rd trimester (32 and 36 weeks), and two postnatal calls (2 and 6 weeks postpartum). Four calls are planned for the partners: at 14-, 22-, and 32-weeks, and at 2-weeks postpartum.
Study NCT03788499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage of Maxillofacial and Oral Cavity
Description: Massage of Maxillofacial and Oral Cavity is performed five times a day, each part lasts 1-2 minutes, repeating 3 cycles. The maxillofacial and oral massage last from the first day of radiotherapy to three months after last radiotherapy.
Study NCT00334490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 12.5 mg Sildenafil once with optional second dose
Study NCT00334490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 12.5 mg orally once with optional second dose
Study NCT00334490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo in 5 mls distilled water
Study NCT01388023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: herbal formula for fresh breath
Description: composition of herbal ingridients in a palatal mucoadhesive patch to remove volatile solfur compounds and reducequantity of vsc creating bacteria
Study NCT01388023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: herbal formula for fresh breath
Description: composition of herbal ingridients in a palatal mucoadhesive patch to remove volatile solfur compounds and reducequantity of vsc creating bacteria
Study NCT02294071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: oral liquid ibuprofen 10mg/kg (maximum 600 mg)
Study NCT02294071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: oral liquid acetaminophen 15mg/kg (max 975mg)
Study NCT01135875 — intervention group
Intervention type: OTHER
Intervention: GBM Patients
Description: 2 teaspoons of blood will be collected during select clinic visits.
Study NCT01135875 — intervention group
Intervention type: OTHER
Intervention: Normal Controls
Description: 2 teaspoons of blood will be collected once.
Study NCT04352218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTA + Stenting using Petalo stent
Description: PTA and Petalo's Stenting are a minimally invasive endovascular procedures, performed by a percutaneous access to the common femoral vein under local anesthesia and Duplex Ultrasound Guidance.
Study NCT04352218 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Description: PTA is a minimally invasive endovascular procedure, performed by a percutaneous access to the common femoral vein under local anesthesia and Duplex Ultrasound Guidance.
Study NCT02157129 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physiologic saline inhalation
Description: Physiologic saline inhalation, 5x/d for 30min
Study NCT03557450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT Scan
Description: PET/CT scanning with sodium fluoride
Study NCT03756922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Description: CFTR corrector
Study NCT01541839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Septal Stapler
Description: This device is a stapler designed to place resorbable implants into the nasal septum. Each device contains 8 staples.
Study NCT02604355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Oral dosing with placebo capsules to match RO7020322.
Study NCT02604355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7020322
Description: Adaptive oral dosing with RO7020322 capsules, starting at 1 mg daily, with ascending or adjusted dosing based on the results of previous dosing.
Study NCT03011983 — intervention group
Intervention type: DEVICE
Intervention: MEG
Description: MEG is a non-invasive functional imaging technique that can measure slow-wave neural activity.
Study NCT03011983 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: MRI is a non-invasive imaging modality that provides measures of brain structure.
Study NCT03011983 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychology assessment
Description: A battery of tests will be administered by a neuropsychologist to evaluate the cognitive function of adolescents with concussion compared to healthy controls.
Study NCT01259375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: Synthetic 9-aminoanthracycline Patients will receive 40mg/m2/day intravenously
Study NCT01167556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Motivational Intervention
Description: A intervention with provided parents 6 sessions of Interaction Skills training and 6 sessions Motivational Interviewing training.
Study NCT01167556 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Motivational Intervention
Description: A intervention with provided parents 6 sessions of Interaction Skills training and 6 sessions Motivational Interviewing training.
Study NCT03825068 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP Block
Description: 20 ml of lacal anaesthetics will be placed below the erector spinae muscle under ultrasound guide
Study NCT03825068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: general anesthetic
Description: patient receive general anaesthetic only
Study NCT02140983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: 90 days of liraglutide up to 1.8mg/day.
Study NCT02140983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo medication
Study NCT00235066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI
Description: PCI with Cypher Sirolimus-Eluting Stent
Study NCT03756922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL176
Description: CFTR potentiator
Study NCT01355822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PETN
Description: Pentaerythrithyltetranitrate: 80 mg orally twice a day
Study NCT01968902 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: incabotulinumtoxinA
Description: A dose of 200 units to 400 units of Xeomin will be injected by EMG-guided technique into the appropriate muscles in the effected leg at injection visit
Study NCT01355822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: orally, twice daily
Study NCT03577925 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HPV genotype test
Description: HPV genotype test is a diagnostic test by smearing the cervix to find out whether a patient is hpv infected, and if infected, the test can descover the concrete hpv genotype.
Study NCT01968902 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection on the day of injection visit
Study NCT00848978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-week aerobic and strength training program
Description: Participants allocated in the intervention group will be enrolled in three weekly non-consecutive training sessions for 8 weeks. Each session will last for about 45-50 min. The exercise program will consist of muscular strength and aerobic exercises. Each session will start and end with a low intensity \~5-7 min warm-up and cool-down period respectively, consisting mainly of stretching exercises involving all major muscle groups.
Study NCT01547247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: soft straight distal cap D-201-14304 Olympus attached to the tip of the colonoscope
Description: Colonoscopy with transparent cap attached to the tip of the colonoscope and water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
Study NCT01547247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: water immersion colonoscopy
Description: Colonoscopy without transparent cap using water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
Study NCT01381458 — intervention group
Intervention type: DRUG
Intervention: FSC
Description: fluticasone propionate / salmeterol xinofoate combination
Study NCT01381458 — intervention group
Intervention type: DRUG
Intervention: ACs
Description: tiotropium alone, ipratropium alone, or in combination with albuterol
Study NCT00802438 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mepolizumab
Description: up to three monthly doses of 750mg i.v. mepolizumab
Study NCT02878460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: monitoring with ORI + SpO2
Description: If ORI is equal to 0.00, the FiO2 (or oxygen flow) is not changed. if ORI is ≥ 0.01, Nurses must decrease the FiO2 (or oxygen flow) by 10%, until ORI is =0.~if SpO2 is \< lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called.